TNF receptor p55 and IL-8₇₂ and IL-8₇₇ isoforms: blood and urine levels in breast cancer patients

Figures & data

Table 1.  Comparative characteristic of content soluble TNF receptor p55 and isoforms of IL-8 in blood plasma and urine of patients with breast cancer and healthy donors.

Investigated groups	Blood plasma^a (all as ng/mL)			Urine^a (all as ng/mL)			Plasma vs. urine (^bP and ^cr values)
	p55	IL-872	IL-877	p55	IL-872	IL-877	p55	IL-872
Patients with breast cancer (n=37)	4.300 (1.100–13.300)	0.020 (0.003–0.160)	<0.030^†	3.500 (0.015–23.400)	0.020 (0.003–0.650)	<0.030^†	0.439 (0.075)	0.529 (0.163)
Healthy donors (n=10)	4.300 (1.800–7.200)	0.025 (0.007–0.180)	<0.030^†	4.900 (2.000–10.700)	0.045 (0.007–0.160)	<0.030^†	0.533 (0.399)	0.315 (0.889)^*
Patients vs. donors (^bP values)	0.404	0.481	—	0.184	0.310	—

^aContinuous variables are expressed as medians and ranges (in parentheses). ^†Below ELISA sensitivity.

^bMann–Whitney U-test (continuous variables). All differences are statistically insignificant (P>0.05).

^cSpearman’s rank correlation coefficient (r values are in parentheses). ^*Positive correlation is statistically significant (P < 0.05).

Table 2.  Comparative characteristic of content soluble TNF receptor p55 and IL-8₇₂ in plasma and urine of patients with breast cancer in the context of cancer stage.

Investigated groups	^aBlood plasma (all ng/mL)		^aUrine (all ng/mL)		Plasma vs. urine (^bP and ^cr values)
	p55	IL-872	p55	IL-872	p55	IL-872
Patients with breast cancer (n=37)
Stage I (n = 5)	4.800 (2.000–13.300)	0.030 (0.005–0.050)	5.500 (0.015–23.400)	0.030 (0.007–0.319)	1.000 (0.400)	0.690 (0.205)
Stage IIA (n = 16)	3.550 (1.500–5.800)	0.010* (0.003–0.040)	1.700 (0.015–12.900)	0.012 (0.003–0.514)	0.224 (0.542)*	0.491 (0.330)
Stage IIB (n = 9)	4.700 (1.100–7.000)	0.040 (0.005–0.160)	5.200 (0.400–16.000)	0.040 (0.007–0.650)	0.605 (0.067)	0.796 (0.066)
Stage IIIA (n = 5)	3.600 (1.700–5.000)	0.030 (0.003–0.048)	3.300 (0.200–4.300)	0.007 (0.003–0.100)	0.421 (0.800)	1.000 (0.100)
Stage IIIB (n = 2)	7.400 (5.100–9.700)	0.050 (0.040– 0.060)	5.500 (4.200–6.800)	0.055 (0.030–0.080)	0.667 (NA)	1.000 (NA)
Healthy donors (n = 10)	4.300 (1.800–7.200)	0.025 (0.007–0.180)	4.900 (2.000–10.700)	0.045 (0.007–0.160)	0.533 (0.399)	0.315 (0.889)*

NA: not applicable.

^aContinuous variables are expressed as medians and ranges (in parentheses). *Difference from healthy donors is statistically significant (P < 0.05). All other differences, including Stage I vs. Stages IIA, IIB, IIIA, and IIIB, are statistically insignificant (P>0.05). Mann–Whitney U-test (continuous variables).

^bMann–Whitney U-test (continuous variables). All differences are statistically insignificant (P < 0.05) (without parentheses).

^cSpearman’s rank correlation coefficient (r values are in parentheses). ^*Positive correlation is statistically significant (P < 0.05).

Table 3.  Comparative characteristic of content soluble TNF receptor p55 and IL-8₇₂ in plasma and urine of patients with breast cancer before and after treatment.

Investigated groups	^aBlood plasma (all ng/mL)		^aUrine (all ng/mL)		Plasma vs. urine (^bP and ^cr values)
	p55	IL-872	p55	IL-872	p55	IL-872
Before treatment (n = 5)	1.700* (1.500–5.200)	0.005 (0.003–0.048)	3.500 (0.200–18.600)	0.007 (0.003–0.319)	0.421 (0.462)	0.690 (0.300)
Neo-adjuvant bloc (n = 6)	2.300 (1.400–9.700)	0.045 (0.003–0.100)	2.850 (0.400–6.800)	0.014 (0.003–0.080)	0.818 (0.609)	0.180 (0.147)
Surgery (n = 11)	4.300 (1.500–13.300)	0.017 (0.003–0.050)	2.100 (0.015–23.400)	0.030 (0.003–0.514)	0.519 (0.100)	0.193 (0.021)
Neo-adjuvant bloc, surgery (n = 9)	4.600 (1.100–5.900)	0.020 (0.005–0.040)	4.300 (0.600–16.000)	0.007 (0.003–0.100)	0.796 (0.126)	0.436 (0.144)
Surgery, adjuvant bloc (n = 10)	3.100 (1.900–7.000)	0.009 (0.004–0.160)	3.500 (0.900–6.700)	0.034 (0.007–0.794)	0.739 (0.109)	0.052 (0.056)
Neo-adjuvant bloc, surgery, adjuvant bloc (n = 2)	3.900 (2.000–5.800)	0.018 (0.006–0.030)	2.508 (0.015–5.000)	0.122 (0.007–0.236)	0.667 (NA)	0.667 (NA)
Healthy donors (n = 10)	4.300 (1.800–7.200)	0.025 (0.007–0.180)	4.900 (2.000–10.700)	0.045 (0.007–0.160)	0.533 (0.399)	0.315 (0.889)*

NA; not applicable.

^aContinuous variables are expressed as medians and ranges (in parentheses). *Difference from healthy donors is statistically significant (P < 0.05). All other differences, including the group before treatment vs. any group after treatment, are statistically insignificant (P>0.05); Mann–Whitney U-test (continuous variables).

^bMann–Whitney U-test (continuous variables). All differences are statistically insignificant (P>0.05) (without parentheses).

^cSpearman’s rank correlation coefficient (r values are in parentheses). ^*Positive correlation is statistically significant (P < 0.05).

Table 4.  Dynamics of TNF receptor p55 and IL-8 isoforms in plasma and urine of patients with breast cancer before and after adjuvant polychemotherapy courses.

Investigated groups		^aBlood plasma (all ng/mL)			^aUrine (all ng/mL)			Plasma vs. urine (^bP and ^cr values)
		p55	IL-872	IL-877	p55	IL-872	IL-877	p55	IL-872
Patients with breast cancer (n = 10)	BAP	3.000 (1.100–4.800)	0.014 (0.003–0.100)	<0.030^†	2.150 (0.400–15.100)	0.007 (0.003–0.514)	<0.030^†	0.796 (0.689)*	0.739 (0.240)
	AAP	2.300* (1.900–5.200)	0.006*, ** (0.003–0.015)	0.058 (0.045–0.105)	4.200 (2.400–6.500)	0.031 (0.010–0.794)	0.048 (0.045–0.076)	0.002* (0.556)	0.0002* (0.031)
Healthy donors (n = 10)		4.300 (1.800–7.200)	0.025 (0.007–0.180)	<0.030^†	4.900 (2.000–10.700)	0.045 (0.007–0.160)	<0.030^†	0.533 (0.399)	0.315 (0.889)*

^aContinuous variables are expressed as medians and ranges (in parentheses). *Difference from healthy donors is statistically significant (P < 0.05); Mann–Whitney U-test (continuous variables). **Difference from BAP is statistically significant (P < 0.05); Wilcoxon’s test (continuous variables).

^†Below ELISA sensitivity.

^bMann–Whitney U-test (continuous variables). *Difference is statistically significant (P < 0.05) (without parentheses).

^cSpearman’s rank correlation coefficient (r values are in parentheses). ^*Positive correlation is statistically significant (P < 0.05).

AAP; after adjuvant polychemotherapy; BAP; before adjuvant polychemotherapy.

Table 5.  Individual levels of TNF receptor p55 and IL-8 isoforms in plasma and urine of patients with breast cancer.

Patient number	Patient age	Cancer stage	Treatment	Blood plasma (all ng/mL)			Urine (all ng/mL)
				p55	IL-872	^†IL-877	p55	IL-872	^†IL-877
1	43	I	Before treatment	2.000	0.005	<0.045	18.600	0.319	<0.045
2	46	IIB	Before treatment	5.200	0.040	<0.015	3.500	0.300	<0.015
3	47	IIIA	Before treatment	1.700	0.048	<0.045	0.200	0.004	<0.045
4	66	IIA	Before treatment	1.700	0.004	<0.045	3.700	0.007	<0.045
5	53	IIA	Before treatment	1.500	<0.003^†	<0.045	3.200	<0.003^†	<0.045
			Polychemotherapy	1.900	0.015	<0.045	2.400	0.048	<0.045
6	67	IIA	Surgery	3.500	0.017	<0.045	7.200	0.043	<0.045
			Polychemotherapy	2.000	0.005	<0.045	4.100	0.011	<0.045
7	47	IIA	Surgery	2.500	0.008	<0.045	12.900	0.514	<0.045
			Polychemotherapy	2.300	0.004	<0.045	3.400	0.794	<0.045
8	40	IIA	Surgery	1.500	0.004	<0.045	10.000	0.166	<0.045
			Polychemotherapy	2.800	0.004	<0.045	2.900	0.034	<0.045
9	47	IIA	Surgery	4.300	0.030	<0.015	1.100	<0.007^†	<0.015
			Polychemotherapy	1.900	0.007	<0.045	3.500	0.010	<0.045
10	47	IIA	Surgery	4.500	0.010	<0.015	0.600	0.017	<0.015
			Polychemotherapy	3.500	0.004	<0.045	37.600	0.036	<0.045
Healthy donors (n = 10) (medians)				4.440	0.041	<0.015	5.710	0.051	<0.015

^†Below ELISA sensitivity.

Table 6.  Comparative characteristic of content soluble TNF receptor p55 and IL-8₇₂ in plasma and urine of patients with breast cancer before treatment (Group 1) and after treatment (Group 2) with surgery (Point 1) and polychemotherapy (Point 2).^a

Patients	^bBlood plasma (all ng/mL)		^bUrine (all ng/mL)		Plasma vs. urine (^cP and ^dr values)
	p55	IL-872	p55	IL-872	p55	IL-872
Before treatment (Group 1, n = 5, Patients 1–5)	1.700* (1.500–5.200)	0.005 (0.003–0.048)	3.500 (0.200–18.600)	0.007 (0.003–0.319)	0.421 (0.462)	0.690 (0.300)
Surgery (Group 2, n = 5, Patients 6–10)	3.500 (1.500–4.500)	0.010 (0.004–0.030)	7.200 (0.600–12.900)	0.043 (0.007–0.514)	0.690 (0.900)*	0.151 (0.800)
Polychemotherapy (Group 2, n = 5, Patients 6–10)	2.000* (1.900–2.800)	0.005* (0.004–0.015)	3.400 (2.400–4.100)	0.034 (0.010–0.794)	0.016* (0.051)	0.032* (0.308)
Healthy donors (n = 10)	4.300 (1.800–7.200)	0.025 (0.007–0.180)	4.900 (2.000–10.700)	0.045 (0.007–0.160)	0.533 (0.399)	0.315 (0.889)*
^eP values (Group 2, surgery vs. Group 2, polychemotherapy)	0.138	0.068	0.225	0.686	–	–

^aArises from information provided in Table 5.

^bContinuous variables are expressed as medians and ranges (in parentheses). *Difference from healthy donors is statistically significant (P < 0.05). Mann–Whitney U-test (continuous variables).

^cMann–Whitney U-test (continuous variables). *Difference is statistically significant (P < 0.05).

^dSpearman’s rank correlation coefficient (r values are in parentheses). Positive correlation is statistically significant (P < 0.05).

^eWilcoxon’s test (continuous variables). Differences are statistically insignificant (P >0.05).